Suppr超能文献

按年龄对肾细胞癌的癌症特异性死亡率进行逐期逐级分析:竞争风险回归分析。

A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.

机构信息

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.

出版信息

Eur Urol. 2011 Dec;60(6):1152-9. doi: 10.1016/j.eururo.2011.07.064. Epub 2011 Aug 5.

Abstract

BACKGROUND

The association of advanced age and cancer control outcomes shows discordant findings.

OBJECTIVE

To evaluate the effect of age on cancer control outcomes in a large population-based cohort of patients diagnosed with renal cell carcinoma (RCC) of all stages.

DESIGN, SETTING, AND PARTICIPANTS: Using the Surveillance Epidemiology and End Results database, 36 333 patients with RCC were identified. The population was stratified according to age:<50, 50-59, 60-69, 70-79, and ≥80 yr. The effect of age on cancer control outcomes was evaluated using competing-risks regression models. Analyses were repeated stage for stage and grade for grade.

MEASUREMENTS

Cancer-specific mortality (CSM) was measured.

RESULTS AND LIMITATIONS

Age categories 50-59, 60-69, 70-79, and ≥80 yr respectively portended a 1.4-, 1.5-, 1.6-, and 1.9-fold higher risk of CSM than age category <50 yr (all p < 0.001). The effect of advanced age was particularly detrimental in patients with stage I disease: 1.8-, 2.3-, 3.2-, and 3.8-fold higher CSM risk for the same age groups, respectively (all p<0.001). The effect of age on CSM was at its peak in patients with stage I, low-grade RCC (1.6-, 2.2-, 3.6-, and 4.3-fold, respectively; all p<0.001) and remained elevated in stage I, high-grade RCC (2.2-, 2.6-, 2.4-, and 3.0-fold higher, respectively; all p<0.05). Conversely, its effect was virtually absent in patients with stage II-IV RCC.

CONCLUSIONS

Our data suggest that stage I RCC may behave in a more aggressive fashion in elderly patients. Further studies are required to confirm the current findings.

摘要

背景

年龄与癌症控制结果之间的关联存在不一致的发现。

目的

评估年龄对所有分期肾细胞癌(RCC)患者的大型基于人群队列的癌症控制结果的影响。

设计、设置和参与者:使用监测、流行病学和最终结果数据库,确定了 36333 例 RCC 患者。人群根据年龄分层:<50 岁、50-59 岁、60-69 岁、70-79 岁和≥80 岁。使用竞争风险回归模型评估年龄对癌症控制结果的影响。按阶段和等级重复分析。

测量

癌症特异性死亡率(CSM)。

结果和局限性

年龄组 50-59 岁、60-69 岁、70-79 岁和≥80 岁分别比年龄组<50 岁的 CSM 风险高 1.4 倍、1.5 倍、1.6 倍和 1.9 倍(均 p<0.001)。年龄较大的影响在 I 期疾病患者中尤为不利:相同年龄组的 CSM 风险分别高 1.8 倍、2.3 倍、3.2 倍和 3.8 倍(均 p<0.001)。年龄对 CSM 的影响在 I 期、低级别 RCC 中达到峰值(分别为 1.6 倍、2.2 倍、3.6 倍和 4.3 倍;均 p<0.001),在 I 期、高级别 RCC 中仍保持升高(分别为 2.2 倍、2.6 倍、2.4 倍和 3.0 倍;均 p<0.05)。相反,其影响在 II-IV 期 RCC 患者中几乎不存在。

结论

我们的数据表明,I 期 RCC 在老年患者中可能表现出更具侵袭性的行为。需要进一步的研究来证实目前的发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验